10 July 2019 - More than half of new drugs entering the German health care system have not been shown to add benefit.
Beate Wieseler and colleagues argue that international drug development processes and policies are responsible and must be reformed.
Medicines regulators around the world are pursuing a strategy aimed at accelerating the development and approval of drugs. These approaches are based on the assumption that faster access to new drugs benefits patients. The rhetoric of novelty and innovation creates an assumption that new products are better than existing ones.